Lentinan
From Wikipedia, the free encyclopedia
Lentinan
|
|
Systematic (IUPAC) name | |
(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihydroxy-6-[ [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-[ [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | |
Identifiers | |
CAS number | |
ATC code | L03 |
PubChem | |
Chemical data | |
Formula | C42H72O36 |
Mol. mass | 1152.99948 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Lentinan is a form of beta-glucan, a strictly purified beta-1,6:beta-1,3-glucan.[1] It is an anti-tumor polysaccharide from the shiitake mushroom and from Lentinus edodes.[1]
Lentinan is one of the host-mediated anti-cancer drugs which has been shown to affect host defense immune systems.[2]
[edit] References
- ^ a b Cancer Guide Includes many abstracts
- ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology 46 (28): 2662–8. PMID 10522061.
[edit] External links
- Lentinan effects (antitumor and others)
|